Ionis Pharmaceuticals (IONS) earnings history
Most recent quarter
- Fiscal period
- Q2 2026
- Period end
- Jun 30, 2026
- EPS actual
- −$0.69
- EPS estimate
- −$1.08
- EPS surprise
- +36.17%
- Revenue surprise
- +41.73%
- Revenue
- $268.0M
- Revenue estimate
- $189.1M
- Reported
- Jul 29, 2026
Ionis Pharmaceuticals reported Q2 2026 results on July 29, 2026. The company posted a loss of $0.69 per share, narrower than the $1.08 loss analysts expected, a 36.17% beat. Revenue was $268.0 million, well above the $189.1 million consensus, a 41.73% beat. Q2 2025 had been profitable, at $0.70 per share on $452.0 million of revenue. Against that quarter, revenue fell about 41%.
Ionis lost money in every full year shown: $1.90 per share in 2022, $2.56 in 2023, $3.04 in 2024 and $2.44 in 2025. Only two of the last 20 quarters were profitable, Q4 2021 at $1.41 and Q2 2025 at $0.70. Those two quarters also brought the largest revenue in the table, $440.0 million and $452.0 million. The widest loss was $1.41 in Q4 2025. Results have still tended to beat expectations. Ionis topped the EPS estimate in 16 of the last 20 quarters.
The company reported its Q3 results between October 29 and November 9 in each of the past five years. That points to late October or early November 2026 for the next report. It will show whether revenue stays above the $246.0 million to $268.0 million of the first half.
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Jul 29, 2026 | −$1.08 | −$0.69 | +36.17% | $268.0M | SEC |
| Q1 2026 | Apr 29, 2026 | −$0.88 | −$0.56 | +36.11% | $246.0M | SEC |
| Q4 2025 | Feb 25, 2026 | −$1.31 | −$1.41 | −7.35% | $203.0M | SEC |
| Q3 2025 | Oct 29, 2025 | −$1.22 | −$0.80 | +34.33% | $157.0M | SEC |
| Q2 2025 | Jul 30, 2025 | −$0.09 | $0.70 | +868.39% | $452.0M | SEC |
| Q1 2025 | Apr 30, 2025 | −$1.10 | −$0.93 | +15.29% | $132.0M | SEC |
| Q4 2024 | Feb 19, 2025 | −$1.12 | −$0.66 | +41.29% | $227.0M | SEC |
| Q3 2024 | Nov 6, 2024 | −$1.14 | −$0.95 | +16.48% | $134.0M | SEC |
| Q2 2024 | Aug 1, 2024 | −$0.94 | −$0.45 | +51.95% | $225.0M | SEC |
| Q1 2024 | May 7, 2024 | −$1.05 | −$0.98 | +6.44% | $119.0M | SEC |
| Q4 2023 | Feb 21, 2024 | −$0.80 | −$0.06 | +92.50% | $325.0M | SEC |
| Q3 2023 | Nov 2, 2023 | −$1.01 | −$1.03 | −2.15% | $144.0M | SEC |
| Q2 2023 | Aug 9, 2023 | −$0.88 | −$0.60 | +32.05% | $188.0M | SEC |
| Q1 2023 | May 3, 2023 | −$0.87 | −$0.87 | +0.02% | $131.0M | SEC |
| Q4 2022 | Feb 22, 2023 | −$0.94 | −$0.37 | +60.63% | $152.0M | SEC |
| Q3 2022 | Nov 9, 2022 | −$0.72 | −$0.33 | +54.38% | $160.0M | SEC |
| Q2 2022 | Aug 9, 2022 | −$0.61 | −$0.74 | −21.29% | $134.0M | SEC |
| Q1 2022 | May 4, 2022 | −$0.69 | −$0.46 | +33.06% | $142.0M | SEC |
| Q4 2021 | Feb 24, 2022 | −$0.04 | $1.41 | +3326.54% | $440.0M | SEC |
| Q3 2021 | Nov 3, 2021 | −$0.49 | −$0.58 | −18.97% | $133.0M | SEC |
Quarterly revenue
Frequently asked questions
When did Ionis Pharmaceuticals (IONS) last report earnings?
Ionis Pharmaceuticals last reported on Jul 29, 2026, covering fiscal Q2 2026.
Did IONS beat earnings estimates?
Yes. Ionis Pharmaceuticals reported EPS of −$0.69 for Q2 2026 against a −$1.08 estimate — a 36.17% beat.
How much revenue did IONS report last quarter?
Ionis Pharmaceuticals reported $268.0M in revenue for Q2 2026, against a consensus estimate of $189.1M.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.